Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo-controlled, phase 2b trial - The Lancet

Por um escritor misterioso

Descrição

Factor XIa inhibition with asundexian after acute non-cardioembolic  ischaemic stroke (PACIFIC-Stroke): an international, randomised,  double-blind, placebo-controlled, phase 2b trial - The Lancet
Factor XIa inhibition with asundexian after acute non
Factor XIa inhibition with asundexian after acute non-cardioembolic  ischaemic stroke (PACIFIC-Stroke): an international, randomised,  double-blind, placebo-controlled, phase 2b trial - The Lancet
Asundexian - Wikipedia
Factor XIa inhibition with asundexian after acute non-cardioembolic  ischaemic stroke (PACIFIC-Stroke): an international, randomised,  double-blind, placebo-controlled, phase 2b trial - The Lancet
A Multicenter, Phase 2, Randomized, Placebo-Controlled, Double
Factor XIa inhibition with asundexian after acute non-cardioembolic  ischaemic stroke (PACIFIC-Stroke): an international, randomised,  double-blind, placebo-controlled, phase 2b trial - The Lancet
Factor XI Inhibition to Uncouple Thrombosis From Hemostasis: JACC
Factor XIa inhibition with asundexian after acute non-cardioembolic  ischaemic stroke (PACIFIC-Stroke): an international, randomised,  double-blind, placebo-controlled, phase 2b trial - The Lancet
Determination of the Potential Clinical Benefits of Small Molecule
Factor XIa inhibition with asundexian after acute non-cardioembolic  ischaemic stroke (PACIFIC-Stroke): an international, randomised,  double-blind, placebo-controlled, phase 2b trial - The Lancet
JCM, Free Full-Text
Factor XIa inhibition with asundexian after acute non-cardioembolic  ischaemic stroke (PACIFIC-Stroke): an international, randomised,  double-blind, placebo-controlled, phase 2b trial - The Lancet
Pharmacology and Clinical Development of Factor XI Inhibitors
Factor XIa inhibition with asundexian after acute non-cardioembolic  ischaemic stroke (PACIFIC-Stroke): an international, randomised,  double-blind, placebo-controlled, phase 2b trial - The Lancet
Anticoagulants to prevent recurrent non-cardioembolic stroke - The
Factor XIa inhibition with asundexian after acute non-cardioembolic  ischaemic stroke (PACIFIC-Stroke): an international, randomised,  double-blind, placebo-controlled, phase 2b trial - The Lancet
Clinical Evaluation of Factor XIa Inhibitor Drugs: JACC Review
Factor XIa inhibition with asundexian after acute non-cardioembolic  ischaemic stroke (PACIFIC-Stroke): an international, randomised,  double-blind, placebo-controlled, phase 2b trial - The Lancet
PDF) Efficacy and Safety of Oral Factor XIa Inhibitors in Stroke
Factor XIa inhibition with asundexian after acute non-cardioembolic  ischaemic stroke (PACIFIC-Stroke): an international, randomised,  double-blind, placebo-controlled, phase 2b trial - The Lancet
Factor XI inhibitors in patients with cardiovascular disease and a
Factor XIa inhibition with asundexian after acute non-cardioembolic  ischaemic stroke (PACIFIC-Stroke): an international, randomised,  double-blind, placebo-controlled, phase 2b trial - The Lancet
Ischaemic stroke despite antiplatelet therapy: Causes and outcomes
de por adulto (o preço varia de acordo com o tamanho do grupo)